Somite AI has raised $47 million in an oversubscribed Series A funding round led by Khosla Ventures, with participation from SciFi VC, the Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto Group Ventures, Pitango HealthTech, TechAviv, Harpoon Ventures, and angel investors including Fidji Simo, CEO of Applications at OpenAI. This brings Somite's total funding to about $60 million. The company is developing DeltaStem, an AI-powered foundation model platform designed to generate any human cell type for any person. DeltaStem uses proprietary capsule technology, developed by co-founder Professor Alon Klein of Harvard, which enables the generation of cell signaling data 1,000 times faster and more efficiently than current methods. Somite's approach addresses challenges in regenerative medicine and stem cell therapy, including high cost, slow development, and scalability issues. The platform aims to enable the production of mature human cell types at scale, with potential applications for diseases such as Duchenne muscular dystrophy, Type 1 Diabetes, orthopedic conditions, muscular diseases, and blood disorders. Founded by CEO Micha Breakstone, Jonathan Rosenfeld, and Professor Alon Klein, Somite's capsule technology allows millions of experiments to be conducted in parallel, efficiently mapping the developmental trajectories of stem cells under varied conditions. The company is currently running experiments at a one-million-condition scale and plans to reach ten million conditions by the end of the year. Somite positions itself as a TechBio company, focusing on developing broad technology platforms for cell therapy using a data-driven approach.